EPICONGRESS BOSTON - SIXTH ANNUAL CONFERENCE BOSTON, MASSACHUSETTS, USA - JULY 21-23, 2015

The Sixth Annual EpiCongress focused on the latest advancements in translational epigenetic research. Speakers from leading academic groups and industrial players presented to an audience composed of researchers and executives from pharmaceutical and biotechnology companies and CROs. The meeting was divided into three major categories: preclinical and clinical progress updates from drug-development companies, including precompetitive epigenetic projects from GlaxoSmithKline, Novartis and Pfizer; description of tool compounds, screening technologies and case stories of their application in target identification and validation; and, academic presentations on novel approaches for mapping the epigenome to molecular targets and clinically relevant endpoints. This report summarizes some of the important presentations from each of these categories.